-+ 0.00%
-+ 0.00%
-+ 0.00%

Oric Pharmaceuticals initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in mCRPC

PUBT·08/03/2026 20:23:45
Listen to the news
Oric Pharmaceuticals initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in mCRPC
  • Oric Pharmaceuticals initiated Himalayas-1, a global Phase 3 registrational trial of rinzimetostat in metastatic castration-resistant prostate cancer previously treated with abiraterone.
  • Study will test rinzimetostat with Bayer’s NUBEQA (darolutamide) versus physician’s choice of an AR inhibitor or docetaxel, targeting delayed disease worsening.
  • Bayer will supply darolutamide at no cost; Oric retains full global development and commercial rights to rinzimetostat.
  • Rinzimetostat program update is expected in 2H 2026; no new clinical results were reported in the filing.
  • Cash and investments totaled $387.6 million as of June 30, 2026; runway forecast into 2H 2028, beyond the first Phase 3 readout.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-330568), on August 03, 2026, and is solely responsible for the information contained therein.